Table 1.

Selected chemotherapy regimens with a significant risk of febrile neutropenia.

Tumor Type	Chemotherapy Regimen	Risk of FN (%)	Reference
Breast cancer	AC (Doxorubicin/Cyclophosphamide)	7–13 *	Truong et al. [13]
	AC⟶D (Doxorubicin/Cyclophosphamide⟶Docetaxel)	25	Perez et al. [14]
	TAC (Docetaxel/Doxorubicin/Cyclophosphamide)	22	Von Minckwitz et al. [15]
	TC (Docetaxel/Cyclophosphamide)	70	Kosaka et al. [16]
	TCH (Docetaxel/Carboplatin/Trastuzumab)	41	Gilbar et al. [17]
	Docetaxel	17	Marty et al. [18]
Bladder cancer	MVAC (Methotrexate/Vinblastine/Doxorubicin/Cisplatin)	26	Sternberg et al. [19]
Cervical cancer	Cisplatin/Paclitaxel	28	Rose et al. [20]
	Cisplatin/Topotecan	18	Long et al. [21]
Gastric cancer	DCF (Docetaxel/Cisplatin/5-FU) †	29	Van Cutsem et al. [22]
	TCF (Docetaxel/Cisplatin/5-FU) ‡	41	Roth et al. [23]
	ECF (Epirubicin/Cisplatin/5-FU)	13–18	Roth et al. [23], Cunningham et al. [24]
	ECX (Epirubicin/Cisplatin/Capecitabine)	11	Cunningham et al. [24]
Germ cell tumors	BEP (Bleomycin/Etoposide/Cisplatin)	13	Fossa et al. [25]
	EP (Etoposide/Cisplatin)	10	Motzer et al. [26]
	VIP (Etoposide/Ifosfamide/Cisplatin)	15	Fujiwara et al. [27]
	VeIP (Vinblastine/Etoposide/Cisplatin)	67	Miller et al. [28]
	TIP (Paclitaxel/Ifosfamide/Cisplatin)	48	Kondagunta et al. [29]
HNSCC	TPF (Docetaxel/Cisplatin/5-FU)	11	Pointreau et al. [30]
NSCLC	Cisplatin/Paclitaxel	16	Schiller et al. [31]
	Cisplatin/Vinorelbine	22	Pujol et al. [32]
	Cisplatin/Docetaxel	5–11	Fossella et al. [33], Schiller et al. [31]
	Cisplatin/Etoposide	54 § 12 ¶	Font et al. [34] Cardenal et al. [35]
	Docetaxel/Carboplatin	26	Millward et al. [36]
Ovarian cancer	Topotecan	42	Swisher et al. [37]
	Docetaxel	33	Verschraegen et al. [38]
	Paclitaxel	22	Omura et al. [39]
Pancreatic cancer	FOLFIRINOX (5-FU/Leucovorin/Oxaliplatin/Irinotecan)	17	Hosein et al. [40]
SCLC	Etoposide/Carboplatin	14	Yilmaz et al. [41]
	Topotecan	28	Von Pawel et al. [42]
	ICE (Ifosfamide/Carboplatin/Etoposide)	24	Lorigan et al. [43]
	CAV (Cyclophosphamide/Doxorubicin/Vincristine)	14	White et al. [44]
Soft tissue sarcoma	MAID (Mesna/Doxorubicin/Ifosfamide/Dacarbazin)	58	Binh Nguyen et al. [45]
	Ifosfamide	18 #, 20 ##	Lorigan et al. [46]

5-FU–5-fluorouracil, HNSCC–Head and neck squamous cell carcinoma, NSCLC–Non-small cell lung cancer, SCLC–Small cell lung cancer, * Results from a systematic meta-analysis (randomized controlled trials and observational studies, respectively), ^† Docetaxel 75 mg/m² D1 + Cisplatin 75 mg/m² D1 + 5-FU 750 mg/m²/day D1–5 q3w, ^‡ Docetaxel 85 mg/m² D1 + Cisplatin 75 mg/m² D1 + 5-FU 300 mg/m²/day D1–14, ^§ Cisplatin 35 mg/m² D1–3 + Etoposide 200 mg/m² D1–3, ^¶ Cisplatin 100 mg/m² D1 + Etoposide 100 mg/m² D1–3, ^# Ifosfamide 3 g/m² 3-h infusion D1–3, ^## Ifosfamide 9 g/m² continuous D1–3. For more information, see Aapro et al. (2011) [11].